{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=93",
    "query": {
      "condition": "Immune Dysfunction",
      "page": 93
    },
    "page_size": 10
  },
  "pagination": {
    "page": 93,
    "page_size": 10,
    "total_count": 20626,
    "total_pages": 2063,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=94&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immune+Dysfunction&page=92&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T18:40:05.667Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01440192",
      "title": "Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage 2 Pulmonary Sarcoidosis",
        "Stage 3 Pulmonary Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "PDA001 (cenplacel-L)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Celularity Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-09",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2018-03-01",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Denver, Colorado • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440192"
    },
    {
      "nct_id": "NCT00388492",
      "title": "BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bellos, Nicholaos C., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-01-11",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00388492"
    },
    {
      "nct_id": "NCT00870792",
      "title": "Physician Focused Intervention to Improve Adherence With HIV Antiretrovirals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infection",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Adherence report",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2002-11",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00870792"
    },
    {
      "nct_id": "NCT07027111",
      "title": "Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Inflammatory Demyelinating Polyneuropathy"
      ],
      "interventions": [
        {
          "name": "NVG-2089",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvig Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2025-04-25",
      "completion_date": "2026-10-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 1,
      "location_summary": "Denton, Texas",
      "locations": [
        {
          "city": "Denton",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07027111"
    },
    {
      "nct_id": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "B-cell Non-Hodgkin Lymphoma (B-NHL)"
      ],
      "interventions": [
        {
          "name": "Odronextamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 515,
      "start_date": "2019-11-13",
      "completion_date": "2028-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 13,
      "location_summary": "Chicago, Illinois • Iowa City, Iowa • Louisville, Kentucky + 9 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03888105"
    },
    {
      "nct_id": "NCT01891994",
      "title": "Extended Dosing With Eltrombopag for Severe Aplastic Anemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Aplastic Anemia (SAA)"
      ],
      "interventions": [
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "2 Years to 100 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-06-28",
      "completion_date": "2022-08-24",
      "has_results": true,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01891994"
    },
    {
      "nct_id": "NCT00061256",
      "title": "The Effect of Alendronate, Calcium, and Vitamin D on Bone Mineral Density in HIV Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Alendronate",
          "type": "DRUG"
        },
        {
          "name": "Calcium carbonate",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 80,
      "start_date": null,
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2009-08-07",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061256"
    },
    {
      "nct_id": "NCT01892345",
      "title": "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2014-04-11",
      "completion_date": "2018-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892345"
    },
    {
      "nct_id": "NCT00604175",
      "title": "Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Sexually Transmitted Diseases"
      ],
      "interventions": [
        {
          "name": "Quadrivalent HPV vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 45 Years · Female only"
      },
      "enrollment_count": 319,
      "start_date": "2008-02",
      "completion_date": "2012-11",
      "has_results": true,
      "last_update_posted_date": "2021-11-04",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 56,
      "location_summary": "Birmingham, Alabama • Alhambra, California • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00604175"
    },
    {
      "nct_id": "NCT06455319",
      "title": "Precision Administration of Anti-thymocyte Globulin With or Without Verapamil",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Anti-thymocyte globulin (ATG)",
          "type": "DRUG"
        },
        {
          "name": "verapamil extended release capsule",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "6 Years to 35 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-11-12",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-11-02T18:40:05.667Z",
      "location_count": 2,
      "location_summary": "Aurora, Colorado • Gainesville, Florida",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06455319"
    }
  ]
}